간편하게 보는 뉴스는 유니콘뉴스
Merck Provides Update on Phase III TrilynX Study in Locally Advanced Head and Neck Cancer

· 등록일 Jun. 25, 2024 09:43

· 업데이트일 2024-06-26 00:00:36

DARMSTADT, GERMANY--(Business Wire / Korea Newswire)--Merck, a leading science and technology company, today announced the discontinuation of the Phase III randomized TrilynX study evaluating xevinapant plus chemoradiotherapy (CRT) in patients with unresected locally advanced squamous cell carcinoma of the head and neck (LA SCCHN). The decision follows a pre-planned interim analysis performed by the study’s Independent Data Monitoring Committee, which found that the trial would be unlikely to meet its primary objective of prolonging event-free survival. Top-line safety data were overall compatible with the chemo-radio sensitizing properties of xevinapant. The company will conduct an in-depth review of the data and will share the results in a peer-reviewed forum.

LA SCCHN has proven to be a difficult-to-treat form of cancer. CRT has remained the standard of care for decades, despite multiple studies designed to improve outcomes with new treatment approaches, including multiple immunotherapy trials.

“We sincerely thank the patients, caregivers and clinical investigators who participated in this trial,” said Danny Bar-Zohar, Global Head of Research & Development and Chief Medical Officer for the Healthcare business sector of Merck. “While we are disappointed by these results, we remain steadfast in our commitment to develop transformative medicines within our oncology portfolio for areas of high unmet need.”

Given the totality of the data, the company decided to also stop the Phase III clinical trial X-Ray Vision (xevinapant plus radiotherapy, compared to placebo plus radiotherapy) in patients who underwent resection of locally advanced head and neck cancer.

Merck is working to develop and deliver new treatment options that exploit the vulnerabilities of tumor cells. The company is exploring modalities including antibody-drug conjugates (ADCs) and DNA damage response (DDR) inhibitors, across multiple tumor types, including many that have proven difficult to treat where there are significant unmet needs for patients. The company’s support for the head and neck cancer community remains steadfast with Erbitux®, approved in combination with radiotherapy for the initial treatment of locally advanced SCCHN, and which continues to be studied in more than 200 active clinical trials, including at least 15 Phase III studies.

About Xevinapant

Xevinapant (formerly known as Debio 1143) is an investigational potent oral small-molecule IAP (inhibitor of apoptosis protein) inhibitor. In March 2021, Merck gained exclusive rights from Debiopharm International SA to develop and commercialize xevinapant worldwide. Xevinapant is not approved for any use anywhere in the world.

Advancing the Future of Cancer Care

At Merck we strive every day to improve the futures of people living with cancer. Our research explores the full potential of promising mechanisms in cancer research, focused on synergistic approaches designed to hit cancer at its core. We are determined to maximize the impact of our standard-of-care treatments and to continue pioneering novel medicines. Our vision is to create a world where more cancer patients will become cancer survivors. Learn more at www.merckgrouponcology.com.

About Merck

Merck, a leading science and technology company, operates across life science, healthcare and electronics. Around 63,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From providing products and services that accelerate drug development and manufacturing as well as discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices - the company is everywhere. In 2023, Merck generated sales of € 21 billion in 65 countries.

Scientific exploration and responsible entrepreneurship have been key to Merck’s technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the business sectors of Merck operate as MilliporeSigma in life science, EMD Serono in healthcare, and EMD Electronics in electronics.

All Merck press releases are distributed by e-mail at the same time they become available on the Merck website. Please go to www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240624549928/en/

Contact Merck
Media Relations
+49 151 1454-9591
[email protected]

Investor Relations
+49 6151 72-3321
[email protected]
This news is a press release provided by Merck KGaA. Korea Newswire follows these editorial guidelines. Merck KGaA News ReleasesSubscribeRSS Merck’s Innovative Oncology Pipeline of DNA Damage Response Inhibitors and Antibody-Drug Conjugates Poised to Advance Cancer Treatment Merck, a leading science and technology company, today shared updates on the company’s oncology pipeline and focused approach to the research and development of potential new medicines designed to improve the futures of people with cancer. This year, the company plans to open multiple n... 6월 4일 09:32 Merck Signs MoU with KAIST to Advance Scientific Collaboration Merck, a leading science and technology company, has signed a non-binding Memorandum of Understanding (MoU) with the Korea Advanced Institute of Science and Technology (KAIST). The academia-industry cooperation aims at advancing the research and development ecosystem in South Korea for ... 5월 30일 10:15 ... More  More News Health Clinical Trials Pharmaceutical R&D Overseas Merck KGaA All News Releases 
인기 기사12.23 19시 기준
스킬맨, 뉴저지--(Business Wire / 뉴스와이어)--매출 기준 세계 최대의 순수 소비자 건강 회사인 켄뷰(Kenvue Inc.)(뉴욕증권거래소: KVUE)는 뉴욕에서 열리는 모건스탠리 글로벌 소비자 콘퍼런스 2023(Morgan Stanley’s Global Consumer & Retail Conference 2023)에 참가한다고 오늘 발표했다. 최고 경영자 겸...
CHICAGO--(Business Wire / Korea Newswire)--NielsenIQ (NIQ), the world’s leading consumer intelligence company, has released its second Environmental, Social and Governance (ESG) Progress Report detailing the Company’s ESG priorities, how it embeds inclusive, sustainable principles...
대전--(뉴스와이어)--레이저 및 에너지 기반 메디컬 솔루션을 제공하는 글로벌 기업 원텍(대표이사 김종원·김정현) 이 11월 15일부터 17일까지 홍콩에서 개최된 코스모프로프 아시아 2023(COSMOPROF ASIA 2023)에 참여했다. 코스모 프로프는 이탈리아, 볼로냐, 미국 라스베이거스 미용 박람회와 함께 세계 3대 미용...
서울--(뉴스와이어)--동남아와 대만 최대의 이커머스 플랫폼 쇼피코리아(지사장 권윤아, Shopee)가 국내 물류센터에 셀러들의 상품을 위탁받아 일괄 물류 대행 서비스를 제공하는 ‘국내 풀필먼트 서비스(Korea Fulfilled by Shopee, 이하 K-FBS)’를 론칭한다고 16일 밝혔다. ...
뉴욕--(Business Wire / 뉴스와이어)--모건 스탠리(Morgan Stanley)(NYSE: MS)가 오늘 북미 및 유럽·중동·아프리카(EMEA)의 23개 기업이 참여하는 최대 규모의 글로벌 데모 데이(Demo Day)를 개최한다. 코호트 회사는 300명 이상의 투자자와 잠재적인 비즈니스 파트너 및 고객을 대상으로 한다. 5개월...
서울--(뉴스와이어)--보도자료 배포 플랫폼 뉴스와이어를 운영하는 코리아뉴스와이어(대표이사 신동호)가 본사를 중구 서소문로 배재정동빌딩으로 이전했다고 17일 밝혔다. 뉴스와이어가 사무실을 이전한 배재정동빌딩 ...
API
fg
유니콘뉴스는 보도자료 배포 서비스입니다.
여기에 뉴스를 등록하면 언론이 보도하고 널리 배포됩니다.